MicroRNA-155 targets p65 to regulate PD-L1 expression in the early pregnancy endometrium.

Sci Rep

Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, People's Republic of China.

Published: March 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Reproductive disorders in dairy cows represent a significant challenge to the advancement of the dairy industry. Pregnancy success is closely related to the mechanism of immune tolerance, with the PD-1/PD-L1 signaling pathway playing a role in immune regulation, which is associated with immune tolerance and pregnancy maintenance. MicroRNAs can regulate pivotal molecules within the signaling pathway, physiological activities, and disease processes. p65 and PD-L1 expression was significantly increased in the early pregnant uterine epithelium. In contrast, the expression of p65 and PD-L1 was homogeneous in the endometrial epithelium of E and P co-stimulated bEECs and changed with the stimulation time and concentration. MiR-155 expression was significantly reduced in the early pregnant uterine epithelium. p65 was identified as a molecular target of miR-155 using a dual luciferase assay and mimics/inhibitor transfection, and miR-155 inhibited p65 expression by binding to the 3'-UTR of p65 mRNA. The regulation of PD-L1 expression by p65 was confirmed through the knockdown of p65 by si-p65 and the overexpression of p65 by pcDNA3.1-p65. In the context of pregnancy, miR-155 was observed to target p65, thereby regulating PD-L1 expression at the endometrial epithelium.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929852PMC
http://dx.doi.org/10.1038/s41598-025-94595-wDOI Listing

Publication Analysis

Top Keywords

pd-l1 expression
16
p65
10
immune tolerance
8
signaling pathway
8
p65 pd-l1
8
early pregnant
8
pregnant uterine
8
uterine epithelium
8
expression p65
8
endometrial epithelium
8

Similar Publications

Nonsmall cell lung cancer (NSCLC) with SMARCA4 deficiency represents a rare subset of lung tumors characterized by early metastasis, poor response to chemotherapy, and unfavorable prognosis. Established therapy strategies for SMARCA4-deficient NSCLC remain elusive. While immune checkpoint inhibitors have been proposed as a potential solution, their efficacy remains uncertain.

View Article and Find Full Text PDF

Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy.

Front Immunol

September 2025

Department of Thoracic Surgery, Shenzhen People's Hospital (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, Guangdong, China.

Background: Lung cancer remains the leading cause of cancer-related mortality globally, primarily due to late-stage diagnosis, molecular heterogeneity, and therapy resistance. Key biomarkers such as EGFR, ALK, KRAS, and PD-1 have revolutionized precision oncology; however, comprehensive structural and clinical validation of these targets is crucial to enhance therapeutic efficacy.

Methods: Protein sequences for EGFR, ALK, KRAS, and PD-1 were retrieved from UniProt and modeled using SWISS-MODEL to generate high-confidence 3D structures.

View Article and Find Full Text PDF

Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications.

Front Immunol

September 2025

Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.

Gliomas are the most common primary malignant tumors of the central nervous system (CNS), and despite progress in molecular diagnostics and targeted therapies, their prognosis remains poor. In recent years, immunotherapy has emerged as a promising treatment modality in cancer therapy. However, the inevitable immune evasion by tumor cells is a key barrier affecting therapeutic efficacy.

View Article and Find Full Text PDF

PD-L1 on ex-vivo Expanded Toll-like-receptor-Bregs Prevents Allograft Rejection by Breg Viability Promotion, CD4T Effector Cell Suppression, and Tregs Induction.

Am J Transplant

September 2025

Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School; Department of Surgery, Massachusetts General Hospital, Harvard Medical School; Department of Surgery, Hospital of the University of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania

Achieving immune tolerance is a key goal in organ transplantation, as it eliminates the need for long-term immunosuppression. Regulatory B cells (Bregs) present a promising strategy for inducing tolerance. Our previous findings demonstrate that the adoptive transfer of ex vivo-expanded murine splenic B regulatory cells, referred to as TLR-Bregs (TLR9/TLR4 stimulation), induces tolerance to allografts.

View Article and Find Full Text PDF

Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade.

Cell Rep Med

September 2025

Biological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. Electronic address:

The success of immune checkpoint inhibitors is limited by multiple factors, including poor T cell infiltration and function within tumors, partly due to a dense extracellular matrix (ECM). Here, we investigate modulating the ECM by targeting integrin α5β1, a major fibronectin-binding and organizing integrin, to improve immunotherapy outcomes. Use of a function-blocking murinized α5β1 antibody reduces fibronectin fibril formation, enhances CD8 T cell transendothelial migration, increases vascular permeability, and decreases vessel-associated collagen.

View Article and Find Full Text PDF